TTK and neoplasm: We showed that 100 mg/kg of CCT271850 is sufficient to inhibit MPS1, in vivo, for at least 24 h in HCT116 human tumour xenografts, by ∼80%, as shown by a decrease in MPS1 autophosphorylation levels.